Home › Cancer Genetics Gets NY State Approval for Thermo Fisher Lung Cancer CDx

Cancer Genetics Gets NY State Approval for Thermo Fisher Lung Cancer CDx

Dec 19, 2017

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has received approval from the New York State Department of Health (NYSDOH) to offer Thermo Fisher Scientific's Oncomine Dx Target Test, a next-generation sequencing-based companion diagnostic for three targeted lung cancer treatments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12
Featured Webinar

Precision Metagenomics to Identify Patients at Risk for Invasive Infection

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

What's Popular?

In Molecular Diagnostics

  1. Natera Waits for ACOG Guidance on Average-Risk NIPT; Pushes Ahead in Oncology, Transplantation

    Premium

  2. LabCorp, Sysmex, Diazyme, and Others Receive FDA Clearances for Assays, Diagnostic Systems in October

  3. Natera's Q3 Revenues Climb 17 Percent

  4. EliTech Instrument Clearance Brings Unique Features to Mid-Size US Labs

    Premium

  5. Rna Diagnostics Raises $5M in Series A Financing Round

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.